Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists

Size: px
Start display at page:

Download "Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists"

Transcription

1 Human Reproduction Vol.21, No.4 pp , 2006 Advance Access publication December 8, doi: /humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists Efstratios M.Kolibianakis 1,3, Evangelos G.Papanikolaou 2, Michel Camus 2, Herman Tournaye 2, André C.Van Steirteghem 2 and Paul Devroey 2 1 Unit for Human Reproduction, Aristotle University, Thessaloniki, Greece and 2 Centre for Reproductive Medicine, Vrije Universiteit Brussel, Brussels, Belgium 3 To whom correspondence and reprint requests should be addressed. Stratis.Kolibianakis@otenet.gr BACKGROUND: The purpose of this study was to evaluate prospectively the association between the achievement of ongoing pregnancy and the time interval from the end of menstruation until the administration of HCG (menstruationfree interval) in patients treated by IVF. METHODS: A fixed dose of 200 IU of recombinant FSH (rfsh) was started in 90 patients on day 2 of the menstrual cycle and daily GnRH antagonist was initiated on day 6 of stimulation. Triggering of final oocyte maturation was performed with IU of HCG as soon as three follicles of 17 mm were present at ultrasound. RESULTS: Single embryo transfer was performed in 64.6% of the patients who reached embryo transfer (53/82). Ongoing pregnancy rate per embryo transfer was 18.3% (95% CI %). The menstruation-free interval significantly predicted the probability of ongoing pregnancy in a logistic regression analysis, controlling for female age and LH on day 1 of stimulation (odds ratio for the menstruation-free interval: 0.70; 95% CI: ). CONCLUSION: The longer the interval from the end of menstruation until the administration of HCG, the lower the probability of ongoing pregnancy in patients stimulated with recombinant FSH and GnRH antagonist for IVF. Key words: GnRH antagonists/menstruation-free interval/recombinant FSH/ongoing pregnancy Introduction During the follicular phase of a natural cycle, endometrium is subjected to the action of steroid hormones, which are secreted by the dominant follicle. Following ovulation, an adequately prepared endometrium is exposed to elevated progesterone levels, secreted by the corpus luteum, and acquires properties that will allow implantation. On the contrary, endometrium during the follicular phase of an IVF cycle is exposed to much higher steroid levels, which are secreted by the multiple developing follicles. Thus, during this time period, endometrium accepts a quantitatively different stimulus compared with the natural cycle. This might lead to an abnormal endometrial quality by the end of the follicular phase. Support for this concept exists at the steroid receptor level in GnRH antagonist IVF cycles. It has been recently shown that ovarian stimulation for IVF induces steroid receptor changes, before HCG administration, similar to those observed in the early luteal phase (Papanikolaou et al., 2005). Moreover, before HCG administration, premature secretory endometrial changes have been detected in GnRH agonist IVF cycles (Marchini et al., 1991). On the day of oocyte retrieval, there is also plenty of evidence showing that abnormalities in the endometrium are usually the rule. In most studies performed, endometrial biopsies reveal advancement of endometrium (for review: Kolibianakis and Devroey, 2002). The importance of the changes observed by the end of the follicular phase for the achievement of ongoing pregnancy has recently been shown. In IVF cycles where biopsies were taken on the day of oocyte retrieval and an embryo transfer was performed a few days later, extreme endometrium advancement was associated with a decreased probability of ongoing pregnancy (Kolibianakis et al., 2002). It was subsequently assumed that by prolonging the follicular phase the abnormalities induced by the abnormal steroid levels might be intensified, thereby compromising endometrial receptivity. Indeed, it was shown that prolongation of the follicular phase by 2 days in GnRH antagonist cycles results in a decreased probability of pregnancy (Kolibianakis et al., 2004a). This was not attributed to differences in embryo quality, as assessed by morphological criteria, but to differences in endometrial histology (Kolibianakis et al., 2005). A similar observation has been reported in GnRH agonist cycles where prolongation of the follicular phase was associated with a decreased probability of pregnancy (Clark et al., 1991). If prolonged exposure of endometrium to unnatural levels of steroid hormones results in histological abnormalities and in 1012 The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org

2 Menstruation-free interval and ongoing pregnancy in IVF turn decreases pregnancy rates, then duration of stimulation might be negatively associated with pregnancy achievement. However, such an association has so far not been established in the literature. What might have been overlooked, though, is that theoretically in order for hormonal exposure to affect it, endometrium should be ready to accept the hormonal stimulus and progress histologically. Therefore, menstruation should have stopped. From that point onwards, the duration of the interval until the administration of HCG might be more important, as circulating steroids are able to act during this period on the re-epithelialized endometrium. The hypothesis tested in the current prospective study was that the interval from the end of menstruation until the day of HCG administration is associated with the probability of ongoing pregnancy in patients treated for IVF with GnRH antagonists and rfsh. Materials and methods Patient population Ninety patients treated by IVF at the Centre for Reproductive Medicine of the Dutch-speaking Brussels Free University from October 2004 until March 2005 were included in the study. Inclusion criteria were age <39 years, body mass index (BMI) between 18 and 29 kg/m 2, presence of both ovaries, absence of endometriomas detected at ultrasound, FSH levels <10 IU/l and basal levels of estradiol (E 2 <80 pg/ml) and progesterone (<1.6 ng/ml) at initiation of stimulation. Patients could enter the study only once and in order to be analysed were required to have reached embryo transfer. An informed consent was obtained by all patients participating in the study. Ovarian stimulation and IVF procedure Stimulation was performed with recombinant FSH (rfsh, Puregon; NV Organon, Oss, The Netherlands) starting in the afternoon of day 2 of the cycle at 200 IU per day. The dose of rfsh remained unchanged during stimulation. Daily GnRH antagonist 0.25 mg (Orgalutran; NV Organon) was used to inhibit premature LH surge and was always started on the morning of day 6 of stimulation. Final oocyte maturation was achieved by the administration of IU of HCG (Pregnyl; Organon) as soon as 3 follicles of 17 mm were present on ultrasound. Steroid levels were measured but were not taken into consideration for the administration of HCG, which was based exclusively on follicular development. Oocyte retrieval was carried out 36 h after HCG administration by transvaginal ultrasound-guided puncture of follicles. Conventional IVF was performed in 25 couples, ICSI in 52 couples and both conventional IVF and ICSI in five couples. ICSI and IVF procedures have been described in detail previously (Van Steirteghem et al., 1993; Devroey and Van Steirteghem, 2004; Devroey et al., 1995; Van Landuyt et al., 2005). As a matter of principle, one or two embryos were transferred on day 3 or day 5 after oocyte retrieval. Embryos were classified as top quality (score 1), medium quality (score 2), and low quality (score 3), as previously described (Staessen et al., 1992; Gardner and Schoolcraft, 1999; Van Landuyt et al., 2005). The mean score of the embryos transferred to each patient was used for the calculation of the mean embryo quality score of all embryos transferred. Luteal supplementation The luteal phase was supplemented with the vaginal administration of 600 mg natural micronized progesterone in three separate doses (Utrogestan; Besins, Brussels, Belgium), starting 1 day after oocyte retrieval and continued until 7 weeks of gestation if pregnancy was achieved. Hormonal measurements Hormonal assessment was performed at initiation of stimulation, on day 6, on day 8 of rfsh stimulation and on the day of HCG administration. Additional blood samples were taken as necessary between antagonist initiation and HCG administration. Serum LH, FSH, HCG, E 2 and progesterone levels were measured by means of the automated Elecsys immunoanalyser (Roche Diagnostics, Mannheim, Germany). Intra- and inter-assay coefficients of variation (CV) were <3 and <4% for LH, <3 and <6% for FSH, <5 and <7% for HCG, <5 and <10% for E 2 and <3 and <5% for progesterone respectively. The inter-assay CV for LH at 0.4 IU/l was 6.6% and at 1.0 IU/l was 2.7%. Ultrasound assessment Ultrasound was performed on day 6 of stimulation and thereafter as necessary in order to ensure that HCG was injected on the first day the patient had 3 follicles of 17 mm. For that purpose, a follicular growth of 2 mm per day was assumed to be present (Kolibianakis et al., 2004a). Outcome measures Pregnancies progressing beyond the 12th week of gestation were considered to be ongoing. Ongoing implantation rate was calculated by dividing the number of gestational sacs with fetal heart beat present at 12 weeks of gestation by the number of embryos transferred. The patients were asked to report the first day they were completely free of menstruation. This day was confirmed as such, during follow-up of ovarian stimulation. The menstruation-free interval was calculated from that day until the day of HCG. The 1st day of period was reported by the patient as the first day during which bleeding was present at the time of awakening (pre-menstrual spotting was not considered as indicating initiation of menstruation). Statistical analysis Power analysis No data were available in GnRH antagonist cycles to accurately estimate sample size for the present study and thus a power analysis in this prospective pilot study could not be performed. A first interim analysis was planned arbitrarily after the first 90 patients had been included. Statistical tests Nominal variables were examined with the use of the exact χ 2 for trend. Metric variables were analysed by the Mann Whitney U-test. The effect of menstruation-free interval on ongoing pregnancy achievement after embryo transfer was examined by robust logistic regression. Variables which entered the model were those that were selected by means of univariate comparisons between patients that did or did not achieve an ongoing pregnancy if P < 0.1. All tests were two-tailed with a confidence level of 95% (P < 0.05). Values are expressed as mean ± SEM. Results Patient and stimulation characteristics Ninety patients started stimulation. Cycles were cancelled in three patients due to lack of response to stimulation after 10 days. In addition, two patients were excluded from analysis 1013

3 E.M.Kolibianakis et al. due to antagonist initiation later than day 6 of stimulation. In a further three patients no embro transfer was performed due to ovarian hyperstimulation syndrome (OHSS) risk. Therefore 82 patients completed an IVF cycle and were further analysed. The mean (± SEM) age of the patients who reached embryo transfer was 32.2 ± 0.4 years. Patients had performed a mean of 1.1 ± 0.2 previous IVF/ICSI trials, while the mean FSH at initiation of stimulation was 7.3 ± 0.2 IU/l. The majority of the couples were treated for male factor infertility (64.6%, n = 53), while 18.3% were treated for tubal infertility (n = 15). In 17.1% of couples (n = 14) no reason for infertility could be identified (unexplained infertility). The mean duration of FSH stimulation was 9.3 ± 0.2 days and the mean total units of rfsh used were 1858 ± 38 IU. A mean of 13.1 ± 0.9 cumulus oocyte complexes (COC) were retrieved and following fertilization a mean of 7.4 ± 0.5 two pronuclear (2PN) oocytes were available (fertilization rate 56.9 ± 2.2%). Single embryo transfer was performed in 64.6% of patients (n = 53). A mean number of 1.4 ± 0.1 embryos were transferred per patient, resulting in a 15.0 ± 3.7% ongoing implantation rate. Ongoing pregnancy rate per oocyte retrieval was 18.3% (95% CI: %). Association between the menstruation-free interval and achievement of ongoing pregnancy after oocyte retrieval Figure 1 shows histograms for duration of menstruation, stimulation and menstruation-free interval in patients treated with Table I. Duration (days) of menstruation, stimulation and the menstruation-free interval in IVF patients stimulated with rfsh and GnRH antagonists who did or did not achieve an ongoing pregnancy Ongoing pregnancy (n = 15) Not pregnant (n = 67) Menstruation 5.1 ± ± Stimulation 9.7 ± ± Menstruation-free interval 4.6 ± ± GnRH antagonist and rfsh. The mean duration of menstruation was 4.8 ± 0.1 days, the mean duration of stimulation was 10.2 ± 0.2 days and the mean duration of the menstruation-free interval was 5.4 ± 0.2 days. Table I shows the duration of menstruation, stimulation and menstruation-free interval in patients who did or did not achieve an ongoing pregnancy. Table II shows the comparison between patients who did or did not achieve an ongoing pregnancy for several continuous and nominal variables. Based on these comparisons the menstruation-free interval, the LH at initiation of stimulation and the female age entered the logistic regression model. The duration of stimulation also met the criteria for entering the logistic regression analysis (P < 0.1). However, due to its significant correlation with the menstruation-free interval from which it is derived (Spearman correlation coefficient: 0.86, P < 0.001), the two parameters could not enter the model simultaneously. For this reason, the model was P Figure 1. Histogram for duration of menstruation, stimulation and the menstruation-free interval in IVF patients stimulated with rfsh and GnRH antagonist. 1014

4 Menstruation-free interval and ongoing pregnancy in IVF Table II. Baseline, stimulation characteristics and embryological data in patients stimulated with rfsh and GnRH antagonists for IVF who did or did not achieve an ongoing pregnancy. Ongoing pregnancy Not pregnant Baseline parameters Female age (years) 30.7 ± ± FSH on day 1 of stimulation (IU/l) 6.9 ± ± LH on day 1 of stimulation (IU/l) 4.7 ± ± No. of previous trials 1.2 ± ± Body mass index (kg/m 2 ) 23.5 ± ± Indication for treatment, n (%) Andrological 10 (66.7) 43 (64.2) Tubal 3 (20.0) 12 (17.9) Idiopathic 2 (13.3) 12 (17.9) Hormones on the day of HCG FSH (IU/l) 14.1 ± ± LH (IU/l) 1.6 ± ± Estradiol (pg/ml) 1909 ± ± Progesterone (ng/ml) 1.3 ± ± Endometrial thickness on the 9.4 ± ± day of HCG (mm) Stimulation outcome Cumulus oocyte complexes retrieved 14.1 ± ± Fertilization rate (%) 63.4 ± ± Two-pronuclear oocytes 8.5 ± ± Embryos transferred 1.4 ± ± Mean embryo quality score 1.3 ± ± Embryos cryopreserved 4.2 ± ± run twice by including each of the two parameters (menstruation-free interval and duration of stimulation) separately, together with female age and LH level on day 1 of stimulation. Robust logistic regression using as dependent variable the achievement of ongoing pregnancy after embryo transfer and as independent variables the female age, the level of LH at initiation of stimulation and the duration of the menstruation-free interval is shown in Table III. A significant effect on the achievement of ongoing pregnancy after embryo transfer was observed for the female age (0.87, 95% CI: ) and the duration of the menstruation-free interval (odds ratio: 0.70, 95% CI: ). The higher the patient s age and the longer the duration of the menstruation-free interval, the lower the probability of achieving an ongoing pregnancy after embryo transfer. When the menstruation-free interval was replaced by duration of stimulation, the model just reached significance (P = 0.049); however, neither the female age (P = 0.057) nor the duration of stimulation (P = 0.066) significantly predicted the probability of ongoing pregnancy in this case. Table III. Robust logistic regression on achievement of ongoing pregnancy after embryo transfer in patients stimulated with rfsh and GnRH antagonists Dependent variable: achievement of ongoing pregnancy P Odds ratio 95% CI Lower P Upper Menstruation-free interval Age at initiation of stimulation LH level on day Ongoing pregnancy rates per embryo transfer in groups of patients defined according to thirdile analysis of the duration of their menstruation, the duration of their stimulation and the duration of their menstruation-free interval is shown in Table IV. A significant trend toward decreased ongoing pregnancy rates was observed with an increased duration of the menstruationfree interval. Such an association was not observed for duration of menstruation or duration of stimulation. Discussion This study demonstrated that in patients stimulated with rfsh and GnRH antagonists for IVF, the longer the duration of the menstruation-free interval, the lower the probability of ongoing pregnancy. This was observed in a logistic regression analysis controlling for LH level at initiation of stimulation and for female age, which was also negatively associated with the probability of ongoing pregnancy. All patients analysed in the current study had normal steroid levels at initiation of stimulation, since there is evidence that elevated progesterone levels might be associated with a decreased probability of pregnancy in GnRH antagonist cycles (Kolibianakis et al., 2004b). All patients were treated equally during the follicular phase, as they received the same fixed dose of rfsh and GnRH antagonist was always started on day 6 of stimulation. Moreover, the follicular phase ended in the same way in all patients, since its prolongation has been shown to adversely affect the probability of pregnancy in GnRH antagonist cycles (Kolibianakis et al., 2004a). This was achieved by administering HCG on the first day that 3 follicles of 17 mm were present on ultrasound. Finally, luteal support was the same for all patients. The menstruation-free interval is a parameter that is relevant for the GnRH antagonist and the short agonist protocol. However, it has not so far been investigated and therefore comparison with existing literature is not possible. It is well known that, in the natural cycle, endometrium needs to be stimulated for a period of days after menstruation stops, in order to acquire progesterone receptors that will allow Table IV. Ongoing pregnancy per embryo transfer in groups of patients defined by percentile analysis (thirdile) of the duration of menstruation, duration of stimulation and duration of the menstruation-free interval Ongoing pregnancy n (%) Menstruation duration days 5/28 (10.7) 5 days 8/35 (22.9) 6 days 4/19 (21.1) Duration of stimulation days 12/48 (25.0) 11 days 1/16 (6.3) days 2/18 (11.1) Menstruation-free interval days 12/44 (27.3) 6 days 2/15(13.3) 7 days 1/23 (4.3) P a Model P = 0.010; Hosmer and Lemeshow test: P = CI = confidence interval. Values in parentheses are percentages. a Exact χ 2 for trend. 1015

5 E.M.Kolibianakis et al. its luteal transformation following ovulation. In the antagonist cycle, the stimulation of endometrium, by steroids that will allow luteal transformation of endometrium following HCG, starts more abruptly by the end of menstruation. This occurs approximately on stimulation day 4 as a result of the increasing steroid levels. Until that time the menstrual endometrium completes its cycle of re-epithelialization. From that point onward, it appears that there is a period of 5 days during which the endometrium is stimulated by abnormally high E 2 levels, progesterone receptors are induced and preparation for luteal transformation is completed. If this menstruation-free interval is prolonged, the probability of ongoing pregnancy appears to be decreased (Table IV). This can be explained by endometrium abnormalities induced by prolonged hormonal stimulation of endometrium by abnormal E 2 levels. These abnormalities might compromise the probability of pregnancy. Acceptance of this concept would entail analysis of endometrium biopsies taking account of the menstruation-free interval. It would be very interesting if hormonal data in the present study were recorded on the first day after the period had stopped. This would have made it possible to associate not only the duration of the menstruation-free interval with the achievement of ongoing pregnancy, but also the hormonal exposure of endometrium during this period with ongoing pregnancy rates. The possibility that embryo quality, which is crucial for implantation, also affected pregnancy rates in this study is unlikely. The low number of embryos transferred in this population (single embryo transfer in 64.6% of patients), in combination with 13.1 COC retrieved per patient, allowed embryos of high morphological quality to be transferred in all patients. As shown in Table II, morphological embryo quality in this study did not significantly affect the probability of pregnancy. Interestingly, ongoing pregnancy was achieved after a minimum menstruation interval of 1 day, in a 29 year old patient who had six COC retrieved, endometrial thickness of 7 mm on the day of HCG and two top-quality embryos transferred. Although conclusions cannot be drawn on the basis of a single case, it has to be assumed that in this patient endometrium acquired receptivity following HCG administration and progesterone supplementation despite being exposed only 1 day to steroid levels after the end of menstruation. Progesterone receptors, whose stimulation by elevated progesterone level in the luteal phase triggers secretory transformation of endometrium, are known to exist during the early follicular phase in the natural cycle. They are increased by the mid- and late follicular phase, being induced by circulating E 2 levels (Lessey et al., 1988; Bouchard et al., 1991). In this patient, who was exposed only 1 day after the end of menstruation to E 2 stimulation, the progesterone receptor content induced was probably able to allow the endometrium to acquire optimal receptivity for implantation and ongoing pregnancy establishment after the HCG signal. In long protocol GnRH agonist cycles (follicular or luteal), menstruation has ended several days before stimulation with FSH is started. Therefore, the endometrium is subjected to steroids as soon as follicular development begins. However, 1016 although the endometrium in the agonist cycle is exposed earlier to steroids, this occurs more progressively when compared with the antagonist cycle. The estradiol rise is known to be delayed compared to what occurs in the antagonist cycle, since in Phase III comparative trials estradiol levels were significantly higher (almost twice as high) on day 6 of stimulation in the antagonist group, and at the same time more follicles were present in the antagonist than in the agonist group (Borm and Mannaerts, 2000). To date, there have been two histological studies of endometrium prior to HCG administration in IVF cycles using GnRH agonists (Marchini et al., 1991) or GnRH antagonists (Papanikolaou et al., 2005). The studies cannot be compared because of differences in their design but it is interesting to note that histological advancement of endometrium was observed in agonist but not in antagonist cycles prior to HCG administration. In conclusion, the current study provides evidence that prolonged duration of stimulation after menstruation ends is associated with a decreased probability of ongoing pregnancy. These data, if confirmed, support the need to adopt milder forms of ovarian stimulation, especially at the time when single embryo transfer has become current practice. Acknowledgements This work was supported by grants from the Fund for Scientific Research Flanders. References Borm G and Mannaerts B (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 15, Bouchard P, Marraoui J, Massai MR, Medalie DA, De Ziegler D, Perrot- Applanat M, Frydman R and Bergeron C (1991) Immunocytochemical localization of oestradiol and progesterone receptors in human endometrium: a tool to assess endometrial maturation. Baillières Clin Obstet Gynaecol 5, Clark L, Stanger J and Brinsmead M (1991) Prolonged follicle stimulation decreases pregnancy rates after in vitro fertilization. Fertil Steril 55, Devroey P and Van Steirteghem A (2004) A review of ten years experience of ICSI. Hum Reprod Update 10, Devroey P, Tjandraprawira K, Mannaerts B, Coelingh Bennink H, Smitz J, Bonduelle M, De Brabanter A and Van Steirteghem AC (1995) A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization. Hum Reprod 2, Gardner DK and Schoolcraft WB (1999) In-vitro culture of human blastocysts. In Jansen R and Mortimer D (eds), Towards Reproductive Certainty: Infertility and Genetics Beyond Parthenon Press, Carnforth, UK, pp Kolibianakis EM and Devroey P (2002) The luteal phase after ovarian stimulation. Reprod Biomed Online 5(Suppl 1), Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A and Devroey P (2002) Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 78, Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2004a) Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 82, Kolibianakis EM, Zikopoulos K, Smitz J, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2004b) Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 19,

6 Menstruation-free interval and ongoing pregnancy in IVF Kolibianakis EM, Bourgain C, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2005) Prolongation of follicular phase by delaying hcg administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod 20, Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL and McCarty KS Jr (1988) Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 67, Marchini M, Fedele L, Bianchi S, Losa GA, Ghisletta M and Candiani GB (1991) Secretory changes in preovulatory endometrium during controlled ovarian hyperstimulation with buserelin acetate and human gonadotropins. Fertil Steril 55, Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H and Devroey P (2005) Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod 20, Staessen C, Camus M, Bollen N, Devroey P and Van Steirteghem AC (1992) The relationship between embryo quality and the occurrence of multiple pregnancies. Fertil Steril 57, Van Landuyt L, De Vos A, Joris H, Verheyen G, Devroey P and Van Steirteghem A (2005) Blastocyst formation in in vitro fertilization versus intracytoplasmic sperm injection cycles: influence of the fertilization procedure. Fertil Steril 83, Van Steirteghem AC, Nagy Z, Joris H, Liu J, Staessen C, Smitz J, Wisanto A and Devroey P (1993) High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod 7, Submitted on August 25, 2005; resubmitted on October 29, 2005; accepted on November 4,

Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF

Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF Human Reproduction Vol.19, No.11 pp. 2490 2496, 2004 Advance Access publication August 19, 2004 doi:10.1093/humrep/deh471 Profound LH suppression after GnRH antagonist administration is associated with

More information

Should we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?

Should we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer? Human Reproduction Vol.19, No.11 pp. 2550 2554, 2004 Advance Access publication August 6, 2004 doi:10.1093/humrep/deh447 Should we advise patients undergoing IVF to start a cycle leading to a day 3 or

More information

Key words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct

Key words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct Human Reproduction Vol.20, No.10 pp. 2887 2892, 2005 Advance Access publication June 24, 2005. doi:10.1093/humrep/dei150 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering

More information

Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study

Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study RBMOnline - Vol 13. No 2. 2006 166-172 Reproductive BioMedicine Online; www.rbmonline.com/article/2261 on web 19 May 2006 Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study

More information

Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study

Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot

More information

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist

More information

Luteal phase rescue after GnRHa triggering Progesterone and Estradiol

Luteal phase rescue after GnRHa triggering Progesterone and Estradiol Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective

More information

Journal of Experimental & Clinical Assisted Reproduction 2007, 4:1

Journal of Experimental & Clinical Assisted Reproduction 2007, 4:1 Journal of Experimental & Clinical Assisted Reproduction BioMed Central Hypothesis Serum estradiol/progesterone ratio on day of embryo transfer may predict reproductive outcome following controlled ovarian

More information

ORIGINAL ARTICLE Reproductive endocrinology

ORIGINAL ARTICLE Reproductive endocrinology Human Reproduction, Vol.24, No.11 pp. 2902 2909, 2009 Advanced Access publication on August 11, 2009 doi:10.1093/humrep/dep290 ORIGINAL ARTICLE Reproductive endocrinology Does the estradiol level on the

More information

A Tale of Three Hormones: hcg, Progesterone and AMH

A Tale of Three Hormones: hcg, Progesterone and AMH A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,

More information

E.G. Papanikolaou 1,2,3, *, G. Pados 1,3, G. Grimbizis 1,3, E. Bili 1,3, L. Kyriazi 3, N.P. Polyzos 4,P.Humaidan 5,H.Tournaye 4,andB.

E.G. Papanikolaou 1,2,3, *, G. Pados 1,3, G. Grimbizis 1,3, E. Bili 1,3, L. Kyriazi 3, N.P. Polyzos 4,P.Humaidan 5,H.Tournaye 4,andB. Human Reproduction, Vol.27, No.6 pp. 1822 1828, 2012 Advanced Access publication on March 14, 2012 doi:10.1093/humrep/des066 ORIGINAL ARTICLE Reproductive endocrinology GnRH-agonist versus GnRH-antagonist

More information

Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment

Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment Human Reproduction Vol., No.11 pp. 319 3197, 5 Advance Access publication July 1, 5. doi:.93/humrep/dei Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to

More information

ORIGINAL ARTICLE Early pregnancy

ORIGINAL ARTICLE Early pregnancy Human Reproduction, Vol.26, No.5 pp. 1020 1024, 2011 Advanced Access publication on February 4, 2011 doi:10.1093/humrep/der012 ORIGINAL ARTICLE Early pregnancy Does cessation of progesterone supplementation

More information

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,

More information

Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used

Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara

More information

Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles

Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra

More information

Hum. Reprod. Advance Access published March 9, 2010

Hum. Reprod. Advance Access published March 9, 2010 Human Reproduction, Vol.00, No.0 pp. 1 6, 2010 doi:10.1093/humrep/deq059 Hum. Reprod. Advance Access published March 9, 2010 ORIGINAL ARTICLE Infertility Avoidance of weekend oocyte retrievals during GnRH

More information

Abstract. Introduction. Materials and methods. Patients and methods

Abstract. Introduction. Materials and methods. Patients and methods RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos

More information

Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY

Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:

More information

Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial

Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial Leader et al. Reproductive Biology and Endocrinology 2013, 11:52 RESEARCH Open Access Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis

More information

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? Human Reproduction Vol.17, No.8 pp. 2022 2026, 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? J.B.Engel, M.Ludwig 1, R.Felberbaum,

More information

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.

More information

Intérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium

Intérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions

More information

EHY Ng, WSB Yeung, PC Ho. Introduction

EHY Ng, WSB Yeung, PC Ho. Introduction Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study EHY Ng, WSB Yeung, PC Ho

More information

A Tale of Three Hormones: hcg, Progesterone and AMH

A Tale of Three Hormones: hcg, Progesterone and AMH A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan

More information

The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study

The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi

More information

2013 Sep.; 24(3):

2013 Sep.; 24(3): Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0159 2013 Sep.; 24(3):159-172 E-mail: randc_journal@163.com Comparison of the Effects and Safety of Mild Ovarian Stimulation

More information

Introduction. ORIGINAL ARTICLE Infertility

Introduction. ORIGINAL ARTICLE Infertility Human Reproduction, Vol.25, No.3 pp. 683 689, 2010 Advanced Access publication on December 15, 2009 doi:10.1093/humrep/dep436 ORIGINAL ARTICLE Infertility Flexible GnRH antagonist protocol versus GnRH

More information

Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles

Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park

More information

Asimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2

Asimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2 Human Reproduction Vol.16, No.4 pp. 663 667, 2001 Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist

More information

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles? J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation

More information

IVF Protocols: Hyper & Hypo-Responders, Implantation

IVF Protocols: Hyper & Hypo-Responders, Implantation IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient

More information

Influence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser

Influence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte

More information

Vanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.

Vanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol

More information

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn) 34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh

More information

Comparison of follitropin-b administered by a pen device with conventional syringe in an ART programme a retrospective study

Comparison of follitropin-b administered by a pen device with conventional syringe in an ART programme a retrospective study Journal of Clinical Pharmacy and Therapeutics (2008) 33, 401 407 ORIGINAL ARTICLE Comparison of follitropin-b administered by a pen device with conventional syringe in an ART programme a retrospective

More information

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic

More information

A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist

A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist 1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang

More information

2013 Sep.; 24(3):

2013 Sep.; 24(3): Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0151 2013 Sep.; 24(3):151-158 E-mail: randc_journal@163.com Reducing the Trigger Dose of Human Chorionic Gonadotrophin Does

More information

Female Reproductive System. Lesson 10

Female Reproductive System. Lesson 10 Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System

More information

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH Reproductive BioMedicine Online (2011) 23, 457 465 www.sciencedirect.com www.rbmonline.com ARTICLE No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant

More information

(1.,, ) (2.,,, )

(1.,, ) (2.,,, ) 33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature

More information

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.

More information

LUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi

LUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency

More information

IN VITRO FERTILIZATION

IN VITRO FERTILIZATION FERTILITY AND STERILITY VOL. 72, NO. 5, NOVEMBER 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION

More information

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin

More information

A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF

A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,

More information

Is it the seed or the soil? Arthur Leader, MD, FRCSC

Is it the seed or the soil? Arthur Leader, MD, FRCSC The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events

More information

Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment

Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,

More information

Herjan Coelingh Bennink, M.D.:j: Andre Van Steirteghem, M.D., Ph.D.* Paul Devroey, M.D., Ph.D.*

Herjan Coelingh Bennink, M.D.:j: Andre Van Steirteghem, M.D., Ph.D.* Paul Devroey, M.D., Ph.D.* J FERTILITY AND STERILITY@ Copyright 't; 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing

More information

Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer

Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and

More information

Serum progesterone levels on the day of hcg trigger and ICSI outcome: a retrospective observational cohort study

Serum progesterone levels on the day of hcg trigger and ICSI outcome: a retrospective observational cohort study International Journal of Reproduction, Contraception, Obstetrics and Gynecology Amin KV et al. Int J Reprod Contracept Obstet Gynecol. 2018 Aug;7(8):3194-3198 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20183316

More information

Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization

Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,

More information

The ganirelix dose-finding study group*

The ganirelix dose-finding study group* Human Reproduction vol.13 no.11 pp.3023 3031, 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent

More information

Key words: controlled ovarian stimulation/ivf/local tolerance/pen device/recombinant FSH

Key words: controlled ovarian stimulation/ivf/local tolerance/pen device/recombinant FSH Human Reproduction Vol.18, No.6 pp. 1200±1204, 2003 DOI: 10.1093/humrep/deg234 An open, randomized single-centre study to compare the ef cacy and convenience of follitropin b administered by a with follitropin

More information

Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *

Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed

More information

The Human Menstrual Cycle

The Human Menstrual Cycle The Human Menstrual Cycle Name: The female human s menstrual cycle is broken into two phases: the Follicular Phase and the Luteal Phase. These two phases are separated by an event called ovulation. (1)

More information

In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF

In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF Human Reproduction Vol.20, No.9 pp. 2426 2433, 2005 Advance Access publication June 9, 2005 doi:10.1093/humrep/dei106 In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist

More information

Blastocyst-stage versus cleavage-stage embryo transfer in women with high oestradiol concentrations: randomized controlled trial

Blastocyst-stage versus cleavage-stage embryo transfer in women with high oestradiol concentrations: randomized controlled trial Reproductive BioMedicine Online (2011) 23, 789 798 www.sciencedirect.com www.rbmonline.com ARTICLE Blastocyst-stage versus cleavage-stage embryo transfer in women with high oestradiol concentrations: randomized

More information

International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN

International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, ISSN http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.31 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 187 191 ISSN 2330-4456 Comparison

More information

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,

More information

Principles of Ovarian Stimulation

Principles of Ovarian Stimulation Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle

More information

LOW RESPONDERS. Poor Ovarian Response, Por

LOW RESPONDERS. Poor Ovarian Response, Por LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients

More information

GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study

GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study Human Reproduction Vol.21, No.7 pp. 1894 1900, 2006 Advance Access publication March 23, 2006. doi:10.1093/humrep/del072 GnRH agonist as luteal phase support in assisted reproduction technique cycles:

More information

Raoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest

Raoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest Raoul Orvieto The Chaim Sheba Medical Center Tel Hashomer, Israel Declared no potential conflict of interest LH in antagonist cycles; is the story really written? Raoul Orvieto M.D. Israel Overview Role

More information

Association of estradiol levels on the day of hcg administration and pregnancy achievement in IVF: a systematic review

Association of estradiol levels on the day of hcg administration and pregnancy achievement in IVF: a systematic review Human Reproduction Vol.19, No.11 pp. 2446 2453, 2004 Advance Access publication October 7, 2004 doi:10.1093/humrep/deh473 Association of estradiol levels on the day of hcg administration and pregnancy

More information

The effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles

The effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles Original Article Obstet Gynecol Sci 2014;57(4):291-296 http://dx.doi.org/10.5468/ogs.2014.57.4.291 pissn 2287-8572 eissn 2287-8580 The effect of luteal phase progesterone supplementation on natural frozen-thawed

More information

Modified natural cycle IVF and mild IVF: a 10 year Swedish experience

Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Reproductive BioMedicine Online (2010) 20, 156 162 www.sciencedirect.com www.rbmonline.com ARTICLE Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Arthur Aanesen *, Karl-Gösta Nygren,

More information

Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial

Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial JBRA Assisted Reproduction ;00(0):000-000 doi: 10.5935/1518-0557.20180039 Original article Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI

More information

Comparison of GnRH agonist with low-dose urinary hcg for induction of final oocyte maturation

Comparison of GnRH agonist with low-dose urinary hcg for induction of final oocyte maturation Basrah Journal Of Surgery COMPARISON OF GNRH AGONIST WITH LOW-DOSE URINARY HCG FOR THE INDUCTION OF FINAL OOCYTE MATURATION IN HIGH-RISK PATIENTS UNDERGOING INTRACYTOPLASMIC SPERM INJECTION-EMBRYO TRANSFER

More information

Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI

Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI Int J Clin Exp Med 2016;9(7):14677-14683 www.ijcem.com /ISSN:1940-5901/IJCEM0026636 Original Article Effects of a low hcg dose of 2000 IU on clinical outcomes of high-responder women undergoing IVF/ICSI

More information

How to make the best use of the natural cycle for frozen-thawed embryo transfer?

How to make the best use of the natural cycle for frozen-thawed embryo transfer? How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University

More information

Abstract. Introduction. RBMOnline - Vol 18. No Reproductive BioMedicine Online; on web 9 December 2008

Abstract. Introduction. RBMOnline - Vol 18. No Reproductive BioMedicine Online;  on web 9 December 2008 RBMOnline - Vol 18. No 2. 2009 276-281 Reproductive BioMedicine Online; www.rbmonline.com/article/3602 on web 9 December 2008 Article GnRH antagonists and endometrial receptivity in oocyte recipients:

More information

Progesterone and clinical outcomes

Progesterone and clinical outcomes Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and

More information

COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL

COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL Nguyen Xuan Hoi1, Nguyen Manh Ha2 1 National Obstetrics and Gynecology Hospital, 2Hanoi Medical Unviversity

More information

Timing ovulation for intrauterine insemination with a GnRH antagonist

Timing ovulation for intrauterine insemination with a GnRH antagonist Human Reproduction Page 1 of 5 Hum. Reprod. Advance Access published November 26, 2004 doi:10.1093/humrep/deh602 Timing ovulation for intrauterine insemination with a GnRH J.L.Gómez-Palomares 1, B.Juliá

More information

No influence of the indication of freeze-all strategy on subsequent outcome to frozen-thawed embryo transfer cycle

No influence of the indication of freeze-all strategy on subsequent outcome to frozen-thawed embryo transfer cycle Original paper No influence of the indication of freeze-all strategy on subsequent outcome to frozen-thawed embryo transfer cycle T. Masschaele 1,2, F. VandekerckhoVe 2, P. de sutter 2, J. Gerris 2 1 AZ

More information

Judith A.F.Huirne, Andre C.D.van Loenen, Roel Schats, Joseph McDonnell, Peter G.A.Hompes, Joop Schoemaker, Roy Homburg and Cornelis B.

Judith A.F.Huirne, Andre C.D.van Loenen, Roel Schats, Joseph McDonnell, Peter G.A.Hompes, Joop Schoemaker, Roy Homburg and Cornelis B. Human Reproduction Vol.20, No.2 pp. 359 367, 2005 Advance Access publication November 26, 2004. doi:10.1093/humrep/deh601 Dose-finding study of daily GnRH antagonist for the prevention of premature LH

More information

Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study

Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study Reproductive BioMedicine Online (2011) 23, 484 489 www.sciencedirect.com www.rbmonline.com ARTICLE Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a

More information

In vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day of HCG injection: An RCT

In vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day of HCG injection: An RCT Int J Reprod BioMed Vol. 15. No. 12. pp: 757-762, December 2017 Original article In vitro fertilization outcome in frozen versus fresh embryo transfer in women with elevated progesterone level on the day

More information

Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome

Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome Reproductive BioMedicine Online (2012) 24, 527 531 www.sciencedirect.com www.rbmonline.com ARTICLE Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome

More information

Assisted Reproduction Unit, American Hospital of Istanbul, Guzelbahce Sokak No. 20, Nisantasi, Istanbul 34365, Turkey

Assisted Reproduction Unit, American Hospital of Istanbul, Guzelbahce Sokak No. 20, Nisantasi, Istanbul 34365, Turkey Human Reproduction Vol.23, No.3 pp. 668 673, 2008 Advance Access publication on January 12, 2008 doi:10.1093/humrep/dem421 GnRH agonist protocol administration in the luteal phase in ICSI ET cycles stimulated

More information

(BMI)=18.0~24.9 kg/m 2 ;

(BMI)=18.0~24.9 kg/m 2 ; 33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV

More information

Highly purified hmg versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists a randomized study

Highly purified hmg versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists a randomized study Human Reproduction Vol.23, No.10 pp. 2346 2351, 2008 Advance Access publication on June 25, 2008 doi:10.1093/humrep/den220 Highly purified hmg versus recombinant FSH in ovarian hyperstimulation with GnRH

More information

10.7 The Reproductive Hormones

10.7 The Reproductive Hormones 10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid

More information

I. ART PROCEDURES. A. In Vitro Fertilization (IVF)

I. ART PROCEDURES. A. In Vitro Fertilization (IVF) DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment

More information

How to make the best use of the natural cycle for frozen-thawed embryo transfer?

How to make the best use of the natural cycle for frozen-thawed embryo transfer? How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University

More information

Hana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang

Hana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang Original Article Obstet Gynecol Sci 2015;58(6):481-486 http://dx.doi.org/10.5468/ogs.2015.58.6.481 pissn 2287-8572 eissn 2287-8580 Effect of second-line surgery on in vitro fertilization outcome in infertile

More information

Središnja medicinska knjižnica

Središnja medicinska knjižnica Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological

More information

Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles

Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles ORIGINAL PAPER / OBSTETRICS Ginekologia Polska 2016, vol. 87, no. 5, 372 377 Copyright 2016 Via Medica ISSN 0017 0011 DOI: 10.5603/GP.2016.0007 Progesterone vaginal capsule versus vaginal gel for luteal

More information

Can 200 IU of hcg replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study

Can 200 IU of hcg replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study Human Reproduction, Vol.24, No.11 pp. 2910 2916, 2009 Advanced Access publication on July 17, 2009 doi:10.1093/humrep/dep253 ORIGINAL ARTICLE Reproductive endocrinology Can 200 IU of hcg replace recombinant

More information

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,

More information

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate

More information

1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.

1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH. 1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH. 2. This causes the anterior pituitary to secrete small quantities of FSH and LH. 3. At this time, the follicles in the

More information

High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol

High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol Human Reproduction, Vol.28, No.2 pp. 442 452, 2013 Advanced Access publication on November 7, 2012 doi:10.1093/humrep/des389 ORIGINAL ARTICLE Reproductive endocrinology High ovarian response does not jeopardize

More information

M Basly, R Achour, S Ben Jemaa, M Chnitir, L Messaoudi, M Chibani, R Rachdi

M Basly, R Achour, S Ben Jemaa, M Chnitir, L Messaoudi, M Chibani, R Rachdi ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 16 Number 3 Flexible Gnrh Antagonist Protocol Versus Gnrh Agonist Long Protocol In Patients With Polycystic Ovary Syndrome Treated For

More information

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization

More information

Understanding Infertility, Evaluations, and Treatment Options

Understanding Infertility, Evaluations, and Treatment Options Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly

More information

AOGS COMMENTARY SHAHAR KOL 1, ROY HOMBURG 2,3, BIRGIT ALSBJERG 4 & PETER HUMAIDAN 5. Abstract

AOGS COMMENTARY SHAHAR KOL 1, ROY HOMBURG 2,3, BIRGIT ALSBJERG 4 & PETER HUMAIDAN 5. Abstract A C TA Obstetricia et Gynecologica AOGS COMMENTARY The gonadotropin-releasing hormone antagonist protocol the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian

More information